Sunday, November 5, 2017
- 9:00AM-11:00AM
-
Abstract Number: 315
Efficacy of a Wearable-Enabled Physical Activity Counselling Program for People with Knee Osteoarthritis
ARHP Orthopedics, Low Back Pain and Rehabilitation Poster- 9:00AM-11:00AM
-
Abstract Number: 516
Efficacy of Adding Iguratimod Therapy in Rheumatoid Arthritis Patients Who Had Inadequate Response to Biologic Dmards
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 425
Efficacy of Monotherapy of the Biologic Dmards in Patients with Rheumatoid Arthritis: Real Life Data from the Hong Kong Biologics Registry
Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response- 9:00AM-11:00AM
-
Abstract Number: 615
Efficacy of Tofacitinib By Background Methotrexate Dose in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Pooled Data from 2 Phase 3 Trials
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 495
Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 598
Efficacy of Ustekinumab in Psoriatic Arthritis Patients By Prior Treatment Exposure and Disease Duration
Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster I- 9:00AM-11:00AM
-
Abstract Number: 512
Efficacy Response to Baricitinib Based on Baseline Characteristics in Patients Who Are Inadequate Responders to Conventional DMARD
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 525
Efficacy, Tolerability and Reasons for Changing Dmards, Biologics and Small Molecule Drugs in RA Patients without RA Lung Disease from a United States Tertiary Referral Center
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster I: Comorbidities and Adverse Events; Efficacy and Safety of Small Molecules- 9:00AM-11:00AM
-
Abstract Number: 706
Elevated Erythrocyte Sedimentation Rate Among Obese Patients with SLE- Not Always a Marker of Disease Activity
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 767
Elevated MeCP2 Expression in Diffuse Cutaneous Systemic Sclerosis Dermal Fibroblasts Is Associated with Anti-Fibrotic Effects
Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics Poster I- 9:00AM-11:00AM
-
Abstract Number: 646
Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) Is a Susceptibility Factor for Early Axial Spa Meeting the ASAS Classification Criteria: Results from the Spondyloarthritis Caught Early and DEvenir des Spondyloarthrites Indifférenciées Récentes Cohorts
Spondyloarthropathies and Psoriatic Arthritis – Pathogenesis, Etiology Poster I- 9:00AM-11:00AM
-
Abstract Number: 686
Endothelial Dysfunction in Systemic Lupus Erythematosus Patients without Cardiovascular events and Risk Factors: Correlation with Microvascular Alterations and angiogenic t Cells
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes- 9:00AM-11:00AM
-
Abstract Number: 489
Endotypic Clustering of Rheumatoid Arthritis Patients through the Use of Tissue Specific Serum Biomarkers Identifies Structural Progressors
Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster I- 9:00AM-11:00AM
-
Abstract Number: 233
Engaging Community Stakeholders through a National Lupus Education Workshop